Skip to main content
. 2022 Sep 21;12:985380. doi: 10.3389/fonc.2022.985380

Table 3.

Tumor Responses per Investigator and BICR Assessment.

Best Response, n (%) Triple Therapy (n = 24)
Investigator BICR
Complete response 8 (33.33%) 8 (33.33%)
Partial response 12 (50.00%) 11 (45.83%)
Stable disease 3 (12.50%) 4 (16.67%)
Progressive disease 1 (4.17%) 1 (4.17%)
Not evaluable 0 0
Objective response rate 20 (83.33%) 19 (79.17%)
Disease control rate 23 (95.83%) 23 (95.83%)